Navigation Links
FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology
Date:12/10/2009

the choice of the adult FAP patient population, selection of cohort size, the dosing regimen, and duration of treatment. The trial is designed to determine safety and tolerability of CEQ508, starting with a dose-escalation phase in which patients will be given one of four escalating concentrations of the drug, contingent upon safety monitoring. This initial part of the clinical trial is expected to take approximately six months. Next, following a safety review, the trial plan calls for a stable-dose phase in which additional patients will receive the highest safe dose. The FDA will permit daily dosing of 18 or more patients for 28 days. A key readout and secondary objective of the trial includes analysis of biomarker beta-catenin expression changes in the gastrointestinal tract of patients determined from biopsy samples obtained prior to taking the drug and at the end of the dosing period.

Cequent's Vice President of Drug Development, Alison Silva, commented, "I want to commend the reviewers at CBER who have been very responsive, providing critical feedback immediately following our submission and throughout the application process. They worked with us so that we could address their questions quickly and effectively to reach a successful conclusion by our action date."

With the FDA approval of Cequent's clinical-trial protocol now in hand, the company has begun working with the proposed clinical center to obtain the necessary institutional approvals. Cequent expects to begin the Phase I clinical trial during the first quarter of 2010 at the Fred Hutchinson Cancer Research Center in Seattle, Washington, part of the Fred Hutchinson/University of Washington Cancer Consortium. The Cancer Consortium maintains a registry of FAP patients and is also one of 40 National Cancer Institute-designated comprehensive cancer centers nationwide. Gideon Steinbach, M.D., Ph.D., is slated to be the principal investigator (PI) of the Cequent trial. Dr. Steinbach is
'/>"/>

SOURCE Cequent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. SRI International Receives National Institutes of Health Grants to Develop Improved Tomographic Imaging Technology
2. The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies
3. U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine)
4. FDA Grants GeoVax Labs, Inc. Request For Pre-IND Meeting
5. Ganeden Biotech Announces Grants for Early Investigators to Research Probiotic GanedenBC30
6. Cephalon Announces that FDA Grants Priority Review of its Supplemental New Drug Application for NUVIGIL as a Treatment for Excessive Sleepiness Associated with Jet Lag Disorder
7. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
8. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
9. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
10. Oasmia: FDA Grants Paclical(R) Orphan Drug Designation for Ovarian Cancer in the USA
11. Rendell Administration Announces Health Research Grants From Tobacco Settlement Funds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... Pharmaceutical Care Management Association (PCMA) President and ... that could reduce prescription fraud and abuse in Medicare ... Opioid Abuse: Fighting Back on Many Fronts ," sponsored ... The briefing featured several government and industry ... fraud. The Centers for Disease Control and Prevention has ...
(Date:9/29/2014)... YORK , Sept. 29, 2014 ... GlobalData,s new report, "EU5 Sigmoidoscopes Market Outlook ... EU5 Sigmoidoscopes market. The report provides value, in ... average prices (in US dollars) within market segments ... Non-Video Sigmoidoscopes and Flexible Non-Video (Fibre) Sigmoidoscopes). ...
(Date:9/29/2014)... SAN DIEGO , 29 de septiembre ... aquí en adelante, Daiichi Sankyo) (TSE: 4568) y Ambit ... conjunta hoy que han llegado a un acuerdo de ... todas las acciones ordinarias de Ambit Biosciences a un ... medio de una oferta de licitación seguida de una ...
Breaking Medicine Technology:PCMA: How Congress Can Fight Prescription Drug Fraud and Abuse 2EU5 Sigmoidoscopes Market Outlook to 2020 2EU5 Sigmoidoscopes Market Outlook to 2020 3Daiichi Sankyo adquiere Ambit Biosciences 2Daiichi Sankyo adquiere Ambit Biosciences 3Daiichi Sankyo adquiere Ambit Biosciences 4Daiichi Sankyo adquiere Ambit Biosciences 5Daiichi Sankyo adquiere Ambit Biosciences 6Daiichi Sankyo adquiere Ambit Biosciences 7Daiichi Sankyo adquiere Ambit Biosciences 8
... 11, 2011 Isis Pharmaceuticals, Inc. (NASDAQ: ... second development candidate, ISIS-AATRx, in its collaboration with GlaxoSmithKline ... payment from GSK for the selection of ISIS-AATRx.  ISIS-AATRx ... caused by alpha-1 antitrypsin deficiency, or AATD, by inhibiting ...
... 11, 2011 Reportlinker.com announces that ... available in its catalogue: ... http://www.reportlinker.com/p0358494/North-American-External-Defibrillator-Market.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Cardiovascular_Devices ... state of the North American external ...
Cached Medicine Technology:Isis Selects Development Candidate, Isis-AATRx, to Treat AATD-Associated Liver Disease 2Isis Selects Development Candidate, Isis-AATRx, to Treat AATD-Associated Liver Disease 3Isis Selects Development Candidate, Isis-AATRx, to Treat AATD-Associated Liver Disease 4North American External Defibrillator Market 2North American External Defibrillator Market 3North American External Defibrillator Market 4North American External Defibrillator Market 5North American External Defibrillator Market 6North American External Defibrillator Market 7
(Date:9/29/2014)... 30, 2014 NAPW honors ... Professional Woman of the Year. Dr. Mondloch is recognized ... preventative medicine As the largest, most-recognized networking organization of ... and profession, the National Association of Professional Women is ... and nearly 300 Local Chapters. , “Initially my goal ...
(Date:9/29/2014)... NAPW honors Natalie W. ... Private Pediatrics of Palm Beach as a 2014 ... leadership in pediatrics and family care with this prestigious ... the country, spanning virtually every industry and profession, the ... vibrant networking community with over 600,000 members and nearly ...
(Date:9/29/2014)... 30, 2014 Top10BestSEOHosting.com is a ... about hosting products. It is headed by a ... The site offers research-based information and factual studies ... in the current market. , Top10BestSEOHosting.com has ... that GoDaddy ( http://www.top10bestseohosting.com/go/GoDaddy.com/ ) and Bluehost are ...
(Date:9/29/2014)... Every autumn, as high school and ... running season takes off! Athletes typically train throughout the ... season. Zensah®, the leading compression apparel company, makes the ... socks for cross country running. , The ... delayed onset muscle soreness (DOMS) throughout training in addition ...
(Date:9/29/2014)... 29, 2014 International Alliance for ... provide students with a certification program that gives ... enhance their own lives, and the lives of ... benefits the community at large, through innovative certification ... the professional practice of fitness, wellness, nutrition, health, ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Announces Victoria J. Mondloch, M.D., Family Medicine and Women's Health, a 2014 Professional Woman of the Year 2Health News:National Association of Professional Women Announces Dr. Natalie W. Geary, Owner / President of Private Pediatrics of Palm Beach, a 2014 Professional Woman of the Year 2Health News:Top10BestSEOHosting.com: New Reviews for Linux Web Hosting Suppliers Available Online 2Health News:Muscle Support and Style With New Compression Leg Sleeves For Cross Country Runners 2Health News:Narconon Louisiana New Life Retreat Announces Stephen Mogavero Now Certified as a Personal Trainer 2
... , WEDNESDAY, June 29 (HealthDay News) -- Variations of a ... at happy faces, a finding that may help improve understanding ... at people,s faces helps us read their emotions, but some ... especially true of people with autism. The ...
... (HealthDay News) -- A new study reveals that 90 percent ... substances started smoking, drinking or using drugs before they were ... of Americans who began using any addictive substance before age ... started using an addictive substance when they were 21 or ...
... The genome of the most common form of ovarian cancer ... surprisingly frequent structural changes in the genome itself, said members ... Baylor College of Medicine ( www.bcm.edu ) Human Genome ... than 300 such tumors. The study was the first to ...
... Aviv Parkinson,s Disease, brought to public awareness by ... difficult to diagnose. It,s also difficult to accurately estimate ... statistics come from small-scale studies, usually based on information ... exist to track how many people have the disease. ...
... Americans experience chronic pain, a condition that costs the nation ... report from the Institute of Medicine. Much of this ... committee that wrote the report. The committee ... to create a cultural transformation in how the nation understands ...
... , WEDNESDAY, June 29 (HealthDay News) -- Giving flu shots ... Flu vaccination is recommended for anyone older than 6 months ... than 6 months, who have the highest rates of flu ... analyzed data from about 1,500 babies who were hospitalized for ...
Cached Medicine News:Health News:Addiction Starts Early in American Society, Report Finds 2Health News:Addiction Starts Early in American Society, Report Finds 3Health News:Sequence of ovarian genome identifies predominant gene mutations, points to possible treatment 2Health News:Sequence of ovarian genome identifies predominant gene mutations, points to possible treatment 3Health News:Sequence of ovarian genome identifies predominant gene mutations, points to possible treatment 4Health News:Getting an accurate read on Parkinson's 2Health News:Getting an accurate read on Parkinson's 3Health News:IOM report calls for cultural transformation of attitudes toward pain and its prevention and management 2Health News:IOM report calls for cultural transformation of attitudes toward pain and its prevention and management 3
Micro-retractor arm 12"....
... designed for the retraction of nerves, vessels, tissue, ... Equalizes brain retraction pressure. Decreases shear injury to ... conjunction with the Budde Halo Retractor. Range of ... 2 mm and 4 mm wide. Quick change ...
Telescopic Diamond-Dissectors for delicate sharp tissue preparation. Total/working lengths 220/240 mm with protective sleeve....
Cone Ring Curettes, length 9" (229 mm), ring diameter (I.D.) 5/16" (8 mm)....
Medicine Products: